Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharma Mar SA ( (ES:PHM) ) has provided an update.
Pharma Mar SA announced that its Chairman and Chief Financial Officer will present to shareholders at the Ordinary General Meeting in Colmenar Viejo, Madrid. This meeting is significant for stakeholders as it provides insights into the company’s current operations and future strategies.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar SA is a biopharmaceutical company focusing on the discovery and development of marine-derived drugs for oncology treatment. The company is a leader in the biotechnology industry, with a strong emphasis on innovation and research in cancer therapeutics.
Average Trading Volume: 65,804
Technical Sentiment Signal: Buy
Current Market Cap: €1.47B
For an in-depth examination of PHM stock, go to TipRanks’ Overview page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue